Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...

London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...

GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned ...

A trial has shown that belantamab mafodotin can reduce the risk of death by 42% in patients with relapsed or refractory ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in ...

GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain ...

Wire 3, a leading provider of high-speed fiber-optic internet, today announced the closing of a $115 million credit facility. The facility, led by Woodforest National Bank, CIBC, and JPMorgan, with ...

Blend has been positioned in the Leaders' Quadrant in AIM Research's prestigious PeMa Quadrant 2024, a comprehensive assessment of the top Generative AI service providers globally. This recognition ...

GSK (GSK) announced “statistically significant and clinically meaningful” overall survival results from a planned interim analysis of the ...

Belantamab Mafodotin shows significant OS benefit, reducing the risk of death by 42% in multiple myeloma at or after first ...

In addition, GSK said its Blenrep drug has been approved for priority review in China to treat sufferers of myeloma, a bone marrow cancer. The regulatory submission is supported by phase III ...